SG Americas Securities LLC purchased a new position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

SG Americas Securities LLC acquired a new stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Free Report) in the second quarter, according to its most recent filing with the SEC. The fund acquired 14,152 shares of the company’s stock, valued at approximately $58,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of ZNTL. Eventide Asset Management LLC raised its position in shares of Zentalis Pharmaceuticals by 47.9% in the fourth quarter. Eventide Asset Management LLC now owns 11,559,975 shares of the company’s stock valued at $175,134,000 after buying an additional 3,745,936 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Zentalis Pharmaceuticals by 20.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,489,709 shares of the company’s stock valued at $54,999,000 after purchasing an additional 585,644 shares in the last quarter. Decheng Capital LLC bought a new stake in shares of Zentalis Pharmaceuticals during the fourth quarter valued at approximately $31,809,000. Charles Schwab Investment Management Inc. raised its holdings in shares of Zentalis Pharmaceuticals by 0.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 445,823 shares of the company’s stock worth $6,754,000 after buying an additional 3,759 shares during the last quarter. Finally, Rafferty Asset Management LLC boosted its holdings in shares of Zentalis Pharmaceuticals by 79.4% in the fourth quarter. Rafferty Asset Management LLC now owns 360,125 shares of the company’s stock worth $5,456,000 after buying an additional 159,439 shares in the last quarter.

Insider activity at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, CFO Cam Gallagher sold 9,597 shares of the business’s stock in a transaction on Friday, May 31st. The shares were sold at an average price of $11.98, for a total value of $114,972.06. Following the completion of the sale, the chief financial officer now directly owns 633,680 shares of the company’s stock, valued at $7,591,486.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC’s website. 6.10% of shares are held by insiders.

Zentalis Pharmaceuticals trading down 4.1%

Shares of Zentalis Pharmaceuticals stock opened at $3.05 on Wednesday. The firm has a market cap of $216.63 million, a PE ratio of -0.92 and a beta of 1.70. Zentalis Pharmaceuticals, Inc. has a 12-month low of $2.83 and a 12-month high of $27.51. The company’s 50-day moving average price is $3.79 and its 200-day moving average price is $9.61.

Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Your Free Report ) last posted its quarterly earnings results on Friday, August 9th. The company reported ($1.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.40). In the same quarter last year, the company posted EPS of ($1.85). As a group, analysts predict that Zentalis Pharmaceuticals, Inc. will record -2.95 earnings per share for the current fiscal year.

Analyst upgrades and downgrades

A number of research firms recently weighed in on ZNTL. Oppenheimer cut their price target on shares of Zentalis Pharmaceuticals from $50.00 to $25.00 and set an “outperform” rating on the stock in a report on Tuesday, June 18th. Wells Fargo & Company lowered Zentalis Pharmaceuticals from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $29.00 to $9.00 in a research note on Tuesday, June 18. Stifel Nicolaus cut their price target on Zentalis Pharmaceuticals from $32.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, June 18th. Wedbush upgraded Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 target price for the company in a research report on Monday, August 12th. Finally, HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Monday, August 12th. Seven investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $11.33.

Check out the latest stock report on ZNTL

Zentalis Pharmaceuticals profile

(Free Report)

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics for the treatment of various types of cancer. Its product candidates include ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase inhibitor for the treatment of advanced solid tumors and hematologic malignancies; in phase 2 clinical trial as monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian, fallopian tube or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian cancer and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 Clinical Trial of Encorafenib and Cetuximab for Mutant Metastatic Colorectal Cancer; and phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.

Featured stories

Want to see what other hedge funds own ZNTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Free Report).

Receive daily news and reviews for Zentalis Pharmaceuticals – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.